| AD | Atopic dermatitis |
| AhR | Aryl hydrocarbon receptor |
| AKBA | 3-Acetyl-11-keto-β-boswellic acid |
| AUC | Area under the concentration–time curve |
| AUC0–24 h | Area under the concentration–time curve from 0 to 24 h |
| BSA | Bovine serum albumin |
| CD/CDs | Cyclodextrin(s) |
| Cmax | Maximum plasma concentration |
| CMCs | Critical micelle concentrations |
| CPE/CPEs | Chemical permeation enhancer(s) |
| DBMNP/DBMNPs | Dissolved bubble microneedle patch(es) |
| DEGEE | Diethylene glycol monoethyl ether |
| DMN/DMNs | Dissolving microneedle(s) |
| DMSO | Dimethyl sulfoxide |
| DNA | Deoxyribonucleic acid |
| DPG | Dipotassium glycyrrhizinate |
| E1 | In vitro release, permeation, reconstructed-skin, or synthetic-membrane evidence |
| E2 | Ex vivo animal- or human-skin evidence |
| E3 | In vivo animal pharmacokinetic, tissue-distribution, efficacy, or safety evidence |
| E4 | Human pharmacokinetic, dermatokinetic, tissue-deposition, or mechanistic evidence |
| E5 | Controlled clinical evidence in humans |
| E6 | Regulatory approval or established commercial use |
| EMLA | Eutectic mixture of local anesthetics |
| ERflux | Flux enhancement ratio |
| Er:YAG | Erbium-doped yttrium aluminum garnet |
| EU | European Union |
| EV/EVs | Extracellular vesicle(s) |
| FDA | U.S. Food and Drug Administration |
| FITC | Fluorescein isothiocyanate |
| FOXM1 | Forkhead box M1 |
| GAIS | Global Aesthetic Improvement Scale |
| G-CSF | Granulocyte colony-stimulating factor |
| GelMA | Gelatin methacryloyl |
| GFP | Green fluorescent protein |
| HAMA | Hyaluronic acid methacrylate |
| HbA1c | Glycated hemoglobin A1c |
| HPC | Hydroxypropyl cellulose |
| HPMC | Hydroxypropyl methylcellulose |
| IFN-γ | Interferon gamma |
| IGA | Investigator Global Assessment |
| IGA-CHE | Investigator Global Assessment for chronic hand eczema |
| IPM | Isopropyl myristate |
| JAK | Janus kinase |
| LHRH | Luteinizing hormone-releasing hormone |
| logD | Logarithm of distribution coefficient |
| LogP | Logarithm of partition coefficient |
| L-Pro2 | N-acetyl-L-proline dodecyl ester |
| MC | Methylcellulose |
| MCP-1 | Monocyte chemoattractant protein-1 |
| MN/MNs | Microneedle(s) |
| MP | Methyl paraben |
| mPASI | Modified Psoriasis Area and Severity Index |
| mRNA | Messenger RNA |
| MRT | Mean residence time |
| MSC | Mesenchymal stem cell(s) |
| MW | Molecular weight |
| NaCMC | Sodium carboxymethyl cellulose |
| NIR | Near-infrared |
| NMP | N-methyl-2-pyrrolidone |
| NSAID | Nonsteroidal anti-inflammatory drug |
| PBS | Phosphate-buffered saline |
| PD-L1 | Programmed death-ligand 1 |
| PEG/PEGs | Polyethylene glycol(s) |
| PG | Propylene glycol |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| PVP | Polyvinylpyrrolidone |
| Q24 | Cumulative amount permeated at 24 h |
| ROS | Reactive oxygen species |
| SC | Stratum corneum |
| SEMA | Semaglutide |
| sEV/sEVs | Small extracellular vesicle(s) |
| siRNA | Small interfering RNA |
| SLN/SLNs | Solid lipid nanoparticle(s) |
| SLS | Sodium lauryl sulfate |
| t1/2 | Elimination half-life |
| TEWL | Transepidermal water loss |
| TGF-β1 | Transforming growth factor beta 1 |
| TPGS | D-α-tocopheryl polyethylene glycol 1000 succinate |
| TRV/TRVs | Tiered-release vesicle(s) |